Europe — EMA
Olanzapine Glenmark Europe
Olanzapine, the active ingredient in Olanzapine Glenmark Europe, is an atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents.
Request sourcing
What is Olanzapine?
Olanzapine, the active ingredient in Olanzapine Glenmark Europe, is an atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents. GNH USA supplies Olanzapine Glenmark Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Olanzapine Glenmark Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Olanzapine used for?
Olanzapine is an atypical antipsychotic that modulates dopaminergic and serotonergic pathways in psychotic disorders. - Schizophrenia: helps reduce positive and negative symptoms and improves overall functioning. - Bipolar I disorder (manic episodes): assists in controlling mood swings, reducing mania severity. - Maintenance therapy for schizophrenia or bipolar disorder: helps prevent relapse and sustain symptom control.
What are the side effects of Olanzapine?
Olanzapine may elicit a range of adverse reactions that vary in frequency and severity.
Common Side Effects: - Weight gain - Sedation - Dry mouth - Constipation - Increased appetite - Dizziness
Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hyperglycaemia or new‑onset diabetes mellitus - Orthostatic hypotension - Seizures - Elevated blood pressure - Leukocytosis or leukopenia
What precautions apply to Olanzapine?
When using OlOlol
- t t t ... ... ... ... ... ... ... ... ... ... ... ... ... ... t t \
